Michael Lytton joined Oxford Bioscience Partners in January 2001, where he is a General Partner. Prior to that, he was Partner, Chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Claros Diagnostic, Decision Biomarkers, Enanta Pharmaceuticals, GPC Biotech (Vice Chairman), Santhera Pharmaceuticals (Chairman), Radius Pharmaceuticals, and VaxInnate Pharmaceuticals. Mr. Lytton also manages Oxford's investments in AVEO Pharmaceuticals and Concentric Medical. Mr. Lytton is Chairman of the Research and Technology Committee of the Immune Disease Institute at Harvard Medical School (formerly the CBR Institute), where he is also a member of the Executive Committee and Board of Trustees. Mr. Lytton also serves on the Board of Directors of Medicines in Need, a non-profit Harvard-based foundation sponsoring clinical development of a novel drug delivery technology to be used for medicines supplied to developing world countries. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. He was a summa cum laude graduate of Princeton University and a recipient of a Fulbright Scholarship for study at the University of London, and he received a JD degree cum laude from Harvard Law School. Mr. Lytton also received a MSc degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine.